3-Epi-25-Hydroxyvitamin D3

3-Epi-25-Hydroxyvitamin D3 (3-epi-25(OH)D3) is a C-3 epimer of 25-hydroxyvitamin D3 generated during hepatic vitamin D3 metabolism, differing only in the α-stereochemistry of its C-3 hydroxyl group, and circulates in adult serum at a weighted mean of approximately 1.72 ng/mL (4.3 nmol/L), representing roughly 6.1% of total 25(OH)D3. Animal data show that dietary 3-epi-25(OH)D3 at 0.5–1 IU/g suppresses serum parathyroid hormone (PTH) in male weanling rats, and supplementation with 20 µg/day vitamin D3 in adult humans raises circulating 3-epi-25(OH)D3 concentrations by 42.1% over 15 weeks, though no confirmed therapeutic benefit in humans has been established.

Origin & History

3-Epi-25-Hydroxyvitamin D3 is an endogenous metabolite produced in the human liver during the metabolism of vitamin D3 (cholecalciferol), which originates from either cutaneous synthesis upon ultraviolet-B irradiation of 7-dehydrocholesterol or from dietary intake of vitamin D3-containing foods and supplements. It is not derived from any botanical source or geographic region, but rather arises as a minor epimeric byproduct of hepatic 25-hydroxylation of vitamin D3, differing from the parent metabolite 25-hydroxyvitamin D3 (25(OH)D3) solely in the stereochemical orientation of the hydroxyl group at carbon position C-3 (α-orientation versus the β-orientation in 25(OH)D3). Concentrations are detectable in virtually all human populations studied, with notably higher proportional levels in infants that decline progressively with age, and levels are influenced by geographic latitude, sunlight exposure, and oral vitamin D3 supplementation.

Historical & Cultural Context

3-Epi-25-Hydroxyvitamin D3 has no history of use in any traditional medicine system, herbal practice, or cultural healing tradition, as it was unknown prior to the development of high-resolution liquid chromatography–tandem mass spectrometry (LC-MS/MS) techniques in the late 20th and early 21st centuries. Its identification as a distinct circulating vitamin D metabolite in human serum emerged from efforts to improve the analytical specificity of vitamin D status testing, with foundational characterization work published in the 2000s and 2010s as researchers recognized that conventional immunoassays could not discriminate between 25(OH)D3 and its C-3 epimer. The compound's biological and clinical relevance was brought to prominence by observations that infants, who had been thought to have unexpectedly high vitamin D levels by immunoassay, in fact had large proportions of 3-epi-25(OH)D3 cross-reacting with antibody-based tests, prompting reassessment of pediatric vitamin D reference ranges. It remains strictly a subject of modern analytical chemistry and clinical laboratory science, with no traditional preparation, ethnobotanical record, or cultural medicinal significance.

Health Benefits

- **Parathyroid Hormone Modulation (Preclinical)**: Animal studies in male weanling rats demonstrate that dietary 3-epi-25(OH)D3 at doses of 0.5–1 IU/g significantly lowers serum PTH, suggesting a potential role in calcium-phosphate homeostasis analogous to but distinct from 25(OH)D3; this effect was not observed in female rats, indicating sex-dependent biological activity.
- **Vitamin D Status Biomarker**: 3-epi-25(OH)D3 circulates at detectable concentrations in up to 96.4% of adult populations and rises proportionally with vitamin D3 supplementation (42.1% increase with 20 µg/day over 15 weeks), making it a quantifiable indicator of vitamin D3 metabolic activity in serum.
- **Potential Contribution to Total Vitamin D Activity**: Because immunoassay-based 25(OH)D3 measurements cross-react with 3-epi-25(OH)D3, the epimer may contribute to apparent total vitamin D bioactivity as measured clinically, though its intrinsic potency at the vitamin D receptor (VDR) relative to 25(OH)D3 has not been rigorously quantified in humans.
- **Differential Pediatric Physiology Marker**: Infants exhibit disproportionately higher proportional concentrations of 3-epi-25(OH)D3 relative to adults, with a progressive age-related decline, suggesting the epimer may reflect distinct metabolic processing of vitamin D3 in developing physiology and could serve as a developmental biomarker.
- **Renal and Inflammatory Disease Indicator**: Observational data link elevated C3-epi-25(OH)D3 proportions to chronic kidney disease severity in patients with rheumatoid arthritis, implying the epimer may accumulate when normal vitamin D metabolic pathways are disrupted and could signal impaired renal 1α-hydroxylation capacity.
- **Assay Calibration and Diagnostic Accuracy**: Recognition of 3-epi-25(OH)D3 as a distinct circulating species is clinically important because its cross-reactivity with conventional immunoassays can overestimate bioavailable 25(OH)D3 by up to several nmol/L, particularly in infants and supplemented individuals, necessitating LC-MS/MS-based discrimination for accurate vitamin D status classification.

How It Works

3-Epi-25-Hydroxyvitamin D3 arises from epimerization of the C-3 hydroxyl group of 25-hydroxyvitamin D3 from the native β-configuration to the α-configuration, a reaction believed to occur in the liver as a minor shunt pathway of vitamin D3 metabolism, though the specific enzyme(s) responsible for this epimerization have not been conclusively identified. At the molecular level, the epimer's altered C-3 stereochemistry is hypothesized to reduce its affinity for vitamin D-binding protein (DBP) and potentially alter its interaction with the nuclear vitamin D receptor (VDR), but direct ligand-binding and transactivation studies in human cell lines are lacking, and no downstream changes in CYP24A1, TRPV6, or other VDR target gene expression attributable specifically to 3-epi-25(OH)D3 have been reported in human studies. In male weanling rats, the compound suppresses PTH secretion from the parathyroid gland, suggesting at minimum partial agonism at calcium-sensing or VDR-mediated pathways governing PTH gene transcription, though the receptor responsible and the effect size relative to equimolar 25(OH)D3 remain uncharacterized. Rising serum concentrations following oral vitamin D3 supplementation confirm that endogenous production scales with substrate availability, indicating the epimerization pathway is not saturable at typical supplemental doses of 20 µg/day.

Scientific Research

The clinical evidence base for 3-epi-25(OH)D3 is confined almost entirely to pharmacokinetic and observational studies focused on its measurement as a biomarker rather than its therapeutic efficacy, representing a very early and limited evidence tier. One randomized controlled trial (NCT01990872) in adults aged ≥50 years receiving 20 µg/day vitamin D3 for 15 weeks documented a statistically significant 42.1% increase in serum 3-epi-25(OH)D3 (P<0.0001) versus a -29.1% reduction in the placebo arm, establishing pharmacodynamic responsiveness but not therapeutic endpoints. A large cross-sectional study of 1,082 Irish adults quantified 3-epi-25(OH)D3 in 96.4% of participants (mean 2.50 nmol/L, median 2.18 nmol/L) using LC-MS/MS, while U.S. NHANES-derived analyses found it quantifiable in 33.4% of white and 15.0% of Black adults at a weighted mean of 1.72 ng/mL, highlighting population-level variability. Preclinical data from male weanling rat models provide the sole evidence of biological activity beyond biomarker status, and no human efficacy trials, meta-analyses, or systematic reviews examining 3-epi-25(OH)D3 as an intervention exist, placing overall evidence quality at the preliminary-to-preclinical level.

Clinical Summary

No clinical trials have evaluated 3-epi-25(OH)D3 as a standalone therapeutic intervention; all human trial data pertain to its measurement as a secondary outcome within vitamin D3 supplementation studies. The most informative trial (NCT01990872, adults ≥50 years, 20 µg/day vitamin D3, 15 weeks) demonstrated that the epimer's serum concentration rises significantly and proportionally with vitamin D3 dosing, confirming endogenous metabolic formation rather than independent pharmacological action. Observational studies suggest that high proportional 3-epi-25(OH)D3 relative to total 25(OH)D3 may correlate with impaired vitamin D metabolism in disease states such as chronic kidney disease and rheumatoid arthritis, where the ratio may serve as a diagnostic confounder in immunoassay-based vitamin D testing. Confidence in any therapeutic role is extremely low given the complete absence of efficacy endpoints, dose-response clinical data, or safety trials for supplemental administration in humans.

Nutritional Profile

3-Epi-25-Hydroxyvitamin D3 is a steroidal secosteroid metabolite with a molecular formula of C27H44O2 and a molecular weight of approximately 400.64 g/mol, sharing this formula with its parent compound 25-hydroxyvitamin D3 (calcifediol). It is not a macronutrient, micronutrient in the dietary sense, or phytochemical; it is a minor endogenous metabolite present in human serum at concentrations typically ranging from 0 to 117 nmol/L (with most adults in the 1–5 nmol/L range) and represents approximately 2–6% of total circulating 25(OH)D3 under normal conditions. It is not present in measurable quantities in foods, not synthesized in the skin, and not available in any nutritional matrix; its circulating level is entirely a function of hepatic epimerization of vitamin D3-derived 25(OH)D3. Bioavailability in the dietary sense is not applicable; absorption and distribution characteristics have not been studied independently from the parent vitamin D3 metabolic cascade.

Preparation & Dosage

- **Research-Grade Analytical Standard (Powder)**: Available at ≥98% purity from specialty chemical suppliers (e.g., Sigma-Aldrich, Cayman Chemical) for use as a reference standard in LC-MS/MS vitamin D metabolite assays; stored at -20°C under inert atmosphere; not formulated for human consumption.
- **Deuterated Isotope-Labeled Form**: Deuterium-labeled variants (e.g., 3-epi-25(OH)D3-d6) are available as internal standards for quantitative mass spectrometry; these are analytical reagents only and carry no dosage context for supplementation.
- **Endogenous Formation via Vitamin D3 Supplementation**: The only practical means by which circulating 3-epi-25(OH)D3 is increased in humans is through oral vitamin D3 (cholecalciferol) supplementation; a dose of 20 µg/day (800 IU/day) for 15 weeks raised serum levels by 42.1% in one RCT, though this was an incidental finding rather than a therapeutic target.
- **No Established Human Supplement Form**: There is no approved, commercially available, or clinically validated supplement formulation of 3-epi-25(OH)D3; no effective dose range, bioavailability data, or standardization specification exists for human use.
- **Preclinical Oral Dosing (Animal Only)**: Male weanling rat studies used dietary concentrations of 0.5–1 IU/g feed to observe PTH suppression; these doses have no validated human equivalent and should not be extrapolated for clinical application.

Synergy & Pairings

No evidence-based synergistic combinations involving 3-epi-25(OH)D3 as an active ingredient have been studied, as it is not used as a supplement; however, its endogenous formation is intrinsically linked to vitamin D3 (cholecalciferol) intake, meaning that combinations supporting vitamin D3 absorption—such as co-administration with dietary fat, magnesium (which supports 25-hydroxylase and 1α-hydroxylase activity), and vitamin K2 (which regulates calcium deposition downstream of VDR activation)—would indirectly influence circulating 3-epi-25(OH)D3 levels. In the context of analytical research, LC-MS/MS measurement of 3-epi-25(OH)D3 is optimally paired with simultaneous quantification of 25(OH)D3, 25(OH)D2, 1,25(OH)2D3, and 24,25(OH)2D3 to provide a complete vitamin D metabolome profile, which represents a methodological rather than pharmacological synergy. Any future therapeutic investigation would logically position 3-epi-25(OH)D3 within the broader vitamin D-calcium-PTH axis alongside calcium and phosphate co-interventions.

Safety & Interactions

No human safety data exist for supplemental or therapeutic administration of 3-epi-25(OH)D3, as it has never been developed as a clinical or nutritional product; all safety inferences are derived from its chemical classification and analytical-grade material safety data sheets. Commercial research-grade powder carries hazard classifications including acute oral, dermal, and inhalation toxicity (H301+H311, H330) and specific target organ toxicity via repeated oral exposure (H372), consistent with the known toxicological profile of vitamin D metabolite analogs at high doses, though these designations reflect laboratory handling scenarios rather than physiological supplementation. No drug interactions, contraindications, or reproductive safety data have been reported, as the compound has not entered clinical pharmacology studies; however, given that it shares structural similarity with 25(OH)D3 and may partially engage VDR or DBP pathways, theoretical risks of vitamin D toxicity syndrome (hypercalcemia, hypercalciuria, nephrocalcinosis) at supraphysiological doses cannot be excluded. Until human pharmacokinetic, dose-escalation, and safety studies are conducted, no safe supplemental dose can be defined, and use outside of controlled research settings is not supported by any regulatory body.